NeoGenomics (NASDAQ:NEO) Surpasses Earnings and Revenue Estimates with Strong Growth

• NeoGenomics (NASDAQ:NEO) reported an earnings per share of $0.05, exceeding analyst estimates of $0.03.
• The company's quarterly revenue reached $201.66 million, beating the consensus estimate of $196.93 million, driven by an 11% year-over-year increase in total revenue and 14% growth in clinical revenue.
• NeoGenomics demonstrates strong financial health with a current ratio of 3.60 and a debt-to-equity ratio of 0.57.

NeoGenomics (NASDAQ:NEO) is a company that specializes in cancer genetics testing and information services. It provides doctors with advanced diagnostic, prognostic, and predictive testing. The company focuses on areas like hematology, which is the study of blood-related diseases, and solid-tumor therapy selection to help guide cancer treatment.

On July 28, 2026, NeoGenomics reports an earnings per share of $0.05, surpassing the analyst estimate of $0.03. As highlighted by Business Wire, the company also announces quarterly revenue of $201.66 million. This figure beats the consensus estimate of $196.93 million and is about $4 million above the company's prior guidance.

This strong performance is driven by an 11% year-over-year increase in total revenue. The growth comes mainly from a 14% climb in clinical revenue. This boost is attributed to a 12% rise in the average revenue per test and a 2% increase in the volume of tests performed during the quarter.

The company's next-generation sequencing (NGS) business shows robust performance, with its revenue growing 26% year-over-year. This segment now accounts for about one-third of total clinical revenue. This success reflects the company's strategy of expanding into solid-tumor and minimal residual disease (MRD) testing.

The company shows strong financial health with a current ratio of 3.60. This suggests it has more than enough assets to cover its short-term liabilities. Its debt-to-equity ratio is 0.57.